acheter-viagra.freehostp.com
- US Toll free:
- Regular US:
- UK:
- Liste des catégories
-
- Alcoolisme
- Alzheimer Et Parkinson
- Analgésiques
- Anti-inflammatoires
- Antiallergiques
- Antibiotiques
- Anticonvulsivants
- Antidépresseurs
- Antifongiques
- Antiparasitaires
- Antiviraux
- Arthrite
- Asthme
- Cancer
- Chirurgie
- Cholestérol
- Contraceptifs
- Diabète
- Diurétiques
- Dysfonction érectile
- Hypertension Artérielle
- Maladies Cardiovasculaires
- Migraines
- Obésité
- Ostéoporose
- Relaxants Musculaires
- Santé Féminine
- Santé Masculine
- Soins De La Peau
- Soins Des Yeux
- Tractus Gastro-intestinal
- Troubles Mentaux
- Troubles Neurologiques
- VIH
- Voies Respiratoires
- Voies Urinaires
Choose Your language:
- Testimonials
-
J'ai reçu la commande très vite. J'étais vraiment impressioné par la vitesse de livraison. Mike
En savoir plus »
-
- Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended ... - MarketWatch (press release)
- Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended
- Actavis wins FDA approval for Ropinirole extended-release tablets - Pharmaceutical Business Review
- Actavis wins FDA approval for Ropinirole extended-release tabletsPharmaceutical Business ReviewActavis Group, a generic pharmaceuticals company, has gained FDA approval for Ropinirole extended-release tablets, 2mg, 4mg, 6mg, 8mg and 12mg
- Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic Requip - The Pharma Letter
- Warner Chilcott sues Watson over Lo Loestrin; Actavis debuts generic RequipThe Pharma LetterSeparately, Switzerland headquartered Actavis Group, which is currently the subject of a 4
- NuPathe Announces First Quarter 2012 Financial Results and Operational Highlights - MarketWatch (press release)
- NuPathe Announces First Quarter 2012 Financial Results and Operational HighlightsMarketWatch (press release)NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery
- Safeguard Scientifics Announces First Quarter 2012 Financial Results - MarketWatch (press release)
- Safeguard Scientifics Announces First Quarter 2012 Financial ResultsMarketWatch (press release)NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery
 |
Ajouter aux favoris |
|---|
 |
S'abonner à la newsletter |
|---|
